Q-omics provides the consensus-scored IRF7 profile across patient tissues and cancer cell-line models. IRF7 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, IRF7 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, IRF7 RNA expression shows 14,073 significant gene co-expression associations, with the highest sampling consensus in LAML. Together, these results highlight KIRC, and LAML as cancer lineages where IRF7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IRF7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IRF7 survival associations across molecular data types. IRF7 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IRF7 RNA expression–survival associations across cancer types. High IRF7 expression shows unfavorable associations in KIRC, ACC, LGG, KICH and LUSC, but favorable associations in SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for IRF7 RNA expression.
This table summarizes IRF7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for IRF7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IRF7 shows higher tumor expression in KIRC, HNSC, STAD, LUAD, BLCA and BRCA. The KIRC box plot shows higher IRF7 RNA expression in tumor versus normal tissue (log2 FC = +2.017, t-test p < 0.001).
This table shows molecular features associated with IRF7 in patient tissues and cancer cell lines. In patient samples, IRF7 shows the broadest associations at the RNA and protein expression levels, with LAML recurring as the lineage with the largest associated feature set. In cancer cell lines, IRF7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and LUNG_NSCLC_LUAD.
